The Nigerian pharmaceutical sector is undergoing a gradual structural shift toward local manufacturing, driven by regulatory reforms, import substitution policies, and increasing investment in healthcare infrastructure. While foreign exchange conditions have shown relative stability in recent periods, the industry remains structurally exposed to imported inputs, elevated financing costs, and working capital intensity. As a result, performance continues to depend on procurement efficiency, cost control, and capital structure discipline.